枳■子黄酮类成分研究

从北枳（ＨｏｖｅｎｉａｄｕｌｃｉｓＴｈｕｎｂ）种子中首次分离并鉴定了４个黄酮类化合物，即双氢山奈酚（ｄｉｈｙｄｒｏｋａｅｍｐｆｅｒｏｌＩ）、槲皮素（ｑｕｅｒｃｅｔｉｎＩＩ）、（＋）３，３′，５′，５，７五羟基双氢黄酮［（＋）３，３′，５′，５，７ｐｅｎｔａｈｙｄｒｏｆｌａｖａｎｏｎｅＩＩ］和（＋）双氢杨梅黄素［（＋）ｄｉｈｙｄｒｏｍｙｒｉｃｅｔｉｎＩＶ］。其中ＩＩ为新化合物，Ｉ和ＩＶ为首次从该属植物中分到。     

鼓槌石斛化学成分的研究

自中药鼓槌石斛(Dendrobium chrysotoxum Lindl.)茎中分离到5个化合物,经光谱(UV,IR,MS,¹HNMR,DIFNOE和¹³CNMR)分析,分别鉴定为β-谷甾醇(I)、鼓槌菲(chrysotoxene,II)、毛兰素(erianin,III)、毛兰菲(confusarin,IV)和鼓槌联苄(chrysotobibenzyl,V)。II是新化合物,V是新天然产物。     

Cholesterol as a risk factor for coronary heart disease in elderly men. The Baltimore Longitudinal Study of Aging.

In order to explore the relationship of cholesterol to coronary heart disease (CHD), defined as angina pectoris, myocardial infarction, and sudden coronary death, in older men, a group of 1052 men, participants in the Baltimore Longitudinal Study on Aging, were examined. Subjects were stratified into three age groups, 28 to 64, 65 to 74, and 75 to 97 years old. In all three age groups, cholesterol was a significant risk factor for CHD. In the oldest age group (n = 250), the relationship between cholesterol and risk was linear (P = .003) as opposed to younger age groups where the relationship was exponential. This study extends the age range in which hypercholesterolemia has been shown to be associated with CHD to include the 75- to 97-year range.     

Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.

Carteolol is a relatively potent nonselective beta-adrenoceptor antagonist with partial agonist activity. It is used topically to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Twice-daily ocular administration of carteolol 1 or 2% lowers IOP by approximately 32% on average in patients with these conditions, an efficacy equivalent to that of timolol 0.25 or 0.5%. Carteolol eyedrops lack local anaesthetic activity, appear to cause less local irritation than timolol, and produce less pronounced decreases in heart rate or dyspnoea, possibly due to partial agonist activity. The latter activity may also improve retinal perfusion. Thus, although additional comparative trials are needed to accurately assess the precise place of carteolol in therapy, this drug offers a useful alternative to timolol in the management of conditions associated with a raised IOP, and may have advantages in older patients with regard to its tolerability profile, although careful monitoring is still wise.